Stockreport

Can Protalix (PLX) Turn Regulatory Setbacks Into a Competitive Advantage in Rare Disease Markets? [Yahoo! Finance]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF BioTherapeutics and Chiesi Group's request to approve a less frequent dosing schedule for Elfabrio in Fabry disease, stating the submitted data was insufficient to confi [Read more]